Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/03/13 | Current report filing |
|
24 | ||
| 09/27/13 | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
260 | ||
| 08/14/13 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
36 | |
| 08/07/13 | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
9 | ||
| 07/09/13 | Current report filing |
|
96 | ||
| 06/21/13 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
35 | |
| 06/21/13 | Annual report pursuant to Section 13 and 15(d) |
|
|
81 | |
| 06/21/13 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
39 | |
| 03/22/13 | Current report filing |
|
49 | ||
| 02/14/13 | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
9 |